Research coordinated at the Universidade de São Paulo's medical school suggests that neurodegenerative diseases involve a far broader immune component than previously appreciated. Published in the journal iScience, the study analysed nearly 600 blood samples from people with and without Alzheimer's disease, Parkinson's disease and multiple sclerosis, cross-referencing them against more than 9,000 autoantibodies catalogued in public databases.
Rather than a single rogue antibody attacking one synaptic target, the team found coordinated autoantibody signatures that correlate with patients' immune status, the extent of neurological damage and disease-specific symptoms. The pattern points to a systemic autoimmune attack on multiple targets at once, and in Alzheimer's it suggests a role for autoantibodies alongside the beta-amyloid plaques that have dominated the field's attention, a reading supported by mouse studies in which reducing B lymphocytes improved neural connections.
The implications for treatment are provocative. If the autoimmune response in neurodegeneration is networked and systemic, therapies aimed at isolated molecular targets may be addressing symptoms of a wider process. The authors argue for strategies that modulate the immune response as a whole, while acknowledging that their analysis is data-driven and still requires confirmation in laboratory and animal models. As the global burden of dementia grows, new mechanistic framings of this kind are precisely what the field needs.